Tag: HER2+
-
Streamlining Care with Patient Navigation: Improving Timely Anti-HER2 Therapy in Early Breast Cancer in LMICs
Background and Rationale In early breast cancer, HER2-positivity demands timely anti-HER2 therapy to optimize outcomes. In low- and middle-income countries (LMICs), health-system constraints—ranging from fragmented care pathways to access barriers—often delay treatment initiation. This retrospective cohort study investigates whether a structured Patient Navigation Program can shorten the time from diagnosis to the start of anti-HER2…
-
Streamlining care through patient navigation: a retrospective cohort study of timely anti-HER2 therapy in early breast cancer in a low-middle income country
Introduction Timely initiation of anti-HER2 therapy is crucial for improving outcomes in patients with HER2-positive early breast cancer. In low- and middle-income countries (LMICs), health-system constraints—ranging from diagnostic delays to limited access to targeted therapies—can hinder timely treatment. This retrospective cohort study examines whether a structured Patient Navigation Program can streamline care, reduce delays, and…
-
LncRNAs and MAPK Signaling in Breast Cancer: Interplay Driving Pathogenesis and Therapy Options
Introduction: The MAPK Landscape in Breast Cancer MAPK signaling is a cornerstone of cellular decision-making, translating external cues into outcomes such as proliferation, differentiation, migration, and survival. In breast cancer, three major MAPK branches—ERK, JNK, and p38—coordinate responses to growth factors, cytokines, and stress signals. While mutations in upstream components frequently hijack this network, noncoding…
-
Living with cancer in Ireland: how personalized treatment is changing outcomes
Growing a new approach: from one-size-fits-all to personalized cancer care In Ireland, the cancer landscape has shifted dramatically in the last decade. The story of Lydia Whelan, a 32-year-old diagnosed with stage 2 HER2+ breast cancer in 2024, reflects a broader national trend: treatments are becoming more tailored, more precise, and more hopeful for patients…
-
Ireland’s Cancer Care: From One-Size-Fits-All to Personalised Treatments
From shock to progress: a new era in Irish cancer care When Lydia Whelan discovered an indentation on her breast in the summer of 2024, she faced more than a diagnosis. The 32-year-old learned she had stage 2 breast cancer, a moment that could have derailed many lives. Instead, it underscored a broader shift in…
-
Living with cancer in Ireland: We’ve moved from a one-size-fits-all treatment
From uniform treatments to personalised cancer care In Ireland, the cancer treatment landscape has shifted dramatically over the last decade. Patients who once faced a one-size-fits-all approach now benefit from personalised strategies that target the biology of their disease. For Lydia Whelan, a 32-year-old diagnosed with stage 2 HER2+ breast cancer in 2024, this evolution…